Cardiovascular Systems Inc (CSII) Receives Average Recommendation of “Buy” from Analysts
Shares of Cardiovascular Systems Inc (NASDAQ:CSII) have received an average recommendation of “Buy” from the eight brokerages that are presently covering the stock. Two equities research analysts have rated the stock with a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $33.40.
CSII has been the topic of several recent research reports. Lake Street Capital initiated coverage on shares of Cardiovascular Systems in a research report on Monday, January 30th. They set a “buy” rating and a $40.00 price objective on the stock. Needham & Company LLC raised their price objective on shares of Cardiovascular Systems from $27.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, January 26th. Zacks Investment Research raised shares of Cardiovascular Systems from a “hold” rating to a “buy” rating and set a $31.00 price objective on the stock in a research report on Tuesday, March 7th. Finally, TheStreet raised shares of Cardiovascular Systems from a “d” rating to a “c-” rating in a research report on Thursday, May 4th.
Shares of Cardiovascular Systems (NASDAQ:CSII) opened at 31.61 on Tuesday. The stock has a 50 day moving average of $30.00 and a 200 day moving average of $27.03. Cardiovascular Systems has a 52-week low of $15.68 and a 52-week high of $32.54. The firm’s market cap is $1.03 billion.
Cardiovascular Systems (NASDAQ:CSII) last issued its quarterly earnings data on Wednesday, May 3rd. The medical device company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). The firm had revenue of $52.10 million for the quarter, compared to analyst estimates of $51.13 million. Cardiovascular Systems had a negative net margin of 14.74% and a negative return on equity of 15.34%. The company’s revenue for the quarter was up 17.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.31) earnings per share. Equities analysts predict that Cardiovascular Systems will post ($0.13) EPS for the current fiscal year.
Several institutional investors have recently added to or reduced their stakes in CSII. Quantbot Technologies LP raised its position in Cardiovascular Systems by 142.3% in the first quarter. Quantbot Technologies LP now owns 5,323 shares of the medical device company’s stock worth $150,000 after buying an additional 3,126 shares in the last quarter. Winslow Evans & Crocker Inc. purchased a new position in Cardiovascular Systems during the first quarter worth approximately $153,000. Old Mutual Global Investors UK Ltd. purchased a new position in Cardiovascular Systems during the first quarter worth approximately $163,000. Clinton Group Inc. purchased a new position in Cardiovascular Systems during the first quarter worth approximately $212,000. Finally, Koch Industries Inc. purchased a new position in Cardiovascular Systems during the first quarter worth approximately $229,000. 72.30% of the stock is currently owned by institutional investors.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
Receive News & Ratings for Cardiovascular Systems Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems Inc and related companies with MarketBeat.com's FREE daily email newsletter.